Novalgen Overview
- Founded
-
2018
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$6.95M
- Investors
-
4
Novalgen General Information
Description
Developer of comprehensive immunotherapy platform designed to make biological medicines. The company's platform develops breakthrough bispecific antibody therapies that can safely harness the immune system to fight cancer, enabling healthcare professionals to get advanced drugs to offer highly effective treatments with therapies that have the fewest possible side effects.
Contact Information
Website
www.novalgen.co.uk
Formerly Known As
Immunocare
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Primary Office
- Argyle House, Joel Street
- Northwood Hills
- London HA6 1NW
- England, United Kingdom
+44 020 0000 0000
Novalgen Timeline
Novalgen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC | 14-Jun-2021 | $6.95M | 000.00 | 000.00 | Completed | Clinical Trials - Phase 1 |
| 1. Early Stage VC (Series A) | 09-Jan-2019 | 000.00 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 1 |
Novalgen Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
| Series A2 | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Ordinary | 2,667,000 | $0.000014 | $1.41 | $1.41 | 1x | $1.41 | 22.07% |
Novalgen Executive Team (4)
Novalgen Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Bharat Thakrar | Self | Chairman | 000 0000 |
| Brian Silver | Self | Board Member | 000 0000 |
| Nilesh Modi | Novalgen | Chief Operating Officer & Board Member | 000 0000 |
| Richard Fagen | Self | Board Member | 000 0000 |
| Samit Hathi | Self | Board Member | 000 0000 |
Novalgen Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Novalgen Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| AlbionVC | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| Convergys Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| UCL Business | University | Minority | 000 0000 | 000000 0 | |
| UCL Technology Fund | Venture Capital | Minority | 000 0000 | 000000 0 |